Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Mar 19;19(3):909.
doi: 10.3390/ijms19030909.

Amino Acid Metabolism and Transport Mechanisms as Potential Antifungal Targets

Affiliations
Review

Amino Acid Metabolism and Transport Mechanisms as Potential Antifungal Targets

Matthew W McCarthy et al. Int J Mol Sci. .

Abstract

Discovering new drugs for treatment of invasive fungal infections is an enduring challenge. There are only three major classes of antifungal agents, and no new class has been introduced into clinical practice in more than a decade. However, recent advances in our understanding of the fungal life cycle, functional genomics, proteomics, and gene mapping have enabled the identification of new drug targets to treat these potentially deadly infections. In this paper, we examine amino acid transport mechanisms and metabolism as potential drug targets to treat invasive fungal infections, including pathogenic yeasts, such as species of Candida and Cryptococcus, as well as molds, such as Aspergillus fumigatus. We also explore the mechanisms by which amino acids may be exploited to identify novel drug targets and review potential hurdles to bringing this approach into clinical practice.

Keywords: amino acid transporters; antifungal targets; cispentacin; icofungipen; metabolism; sinefungin.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Comparative structures of proline, cispentacin, and icofungipen.
Figure 2
Figure 2
Comparative structures of S-adenosylmethionine and sinefungin.

Similar articles

Cited by

References

    1. McCarthy M.W., Kontoyiannis D.P., Cornely O.A., Perfect J.R., Walsh T.J. Novel Agents and Drug Targets to Meet the Challenges of Resistant Fungi. J. Infect. Dis. 2017;216(Suppl. S3):S474–S483. doi: 10.1093/infdis/jix130. - DOI - PubMed
    1. McCarthy M.W., Walsh T.J. Drug development challenges and strategies to address emerging and resistant fungal pathogens. Expert Rev. Anti-Infect. Ther. 2017;15:577–584. doi: 10.1080/14787210.2017.1328279. - DOI - PubMed
    1. Brown D.W., Baker S.E. Mycotoxins: A Fungal Genomics Perspective. Methods Mol. Biol. 2017;1542:367–379. - PubMed
    1. Osherov N., Kontoyiannis D.P. The anti-Aspergillus drug pipeline: Is the glass half full or empty? Med. Mycol. 2017;55:118–124. doi: 10.1093/mmy/myw060. - DOI - PubMed
    1. Denning D.W. Echinocandin antifungal drugs. Lancet. 2003;362:1142–1151. doi: 10.1016/S0140-6736(03)14472-8. - DOI - PubMed

LinkOut - more resources